Parallax Volatility Advisers
ADPT icon

Parallax Volatility Advisers’s Adaptive Biotechnologies ADPT Stock Holding History

Parallax Volatility Advisers’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-36,000
Closed -$1.47M – 2942
2021
Q2 		$1.47M Hold
36,000
– – ﹤0.01% 1770
2021
Q1 		$1.45M Sell
36,000
-64,000
-64% -$3.46M ﹤0.01% 1906
2020
Q4 		$5.91M Buy
+100,000
New +$5.16M ﹤0.01% 1343

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
BWLSA
Blue Water Life Science Advisors Larkspur, California $159M AUM 139.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Parallax Volatility Advisers's ADPT Position: Q3 2021 in Review

Parallax Volatility Advisers sold out of Adaptive Biotechnologies (ADPT) in Q3 2021, closing a stake of 23,703 shares — an estimated $969K sold.

Parallax Volatility Advisers first reported a position in ADPT in Q4 2020 and held it in 3 quarters. The position peaked at $969K in Q2 2021. 219 funds tracked by Wall St. Rank hold ADPT as of Q3 2021.

  • Parallax Volatility Advisers reported no remaining Adaptive Biotechnologies position as of Q3 2021 after selling out during the quarter.
  • Parallax Volatility Advisers sold 23,703 Adaptive Biotechnologies shares in Q3 2021, an estimated $969K.
  • Parallax Volatility Advisers first reported a position in Adaptive Biotechnologies in Q4 2020 and held it in 3 quarters.
  • Parallax Volatility Advisers's Adaptive Biotechnologies position peaked at $969K in Q2 2021.
  • 219 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q3 2021.

Based on Parallax Volatility Advisers's 13F filing for Q3 2021, filed 15 Nov 2021.